SAVA Technologies secures £6.3m seed funding led by Balderton Capital and Exor Ventures
Balderton Capital and Exor Ventures have led a seed round to help finance clinical trials and expand manufacturing capabilities.
SAVA Technologies develops wearable biosensors designed to track multiple biomarkers from beneath the skin. Its initial product provides an affordable continuous glucose monitoring solution for diabetes patients.
London-based health tech start-up SAVA Technologies has secured £6.3m in a seed funding round. The financing was jointly led by Balderton Capital and Exor Ventures. The company intends to direct the capital towards team expansion, developing its next-generation product line with high-throughput manufacturing, and validating the platform's clinical performance.
Emerging from a five-year stealth period, SAVA is developing a multi-molecule microsensing wearable designed to monitor biomarkers just beneath the skin. The fresh capital arrives shortly after the firm secured MHRA approval to advance its first clinical trials for diabetes management.
From the founder
"At SAVA we are tackling preventable illness by building a new operating system for health monitoring. Our microsensor will revolutionise healthcare by making world-leading monitoring technology available to all. With this capital, we can accelerate our goal of creating a new paradigm for healthcare – preventative, personalised and painless."
Renato Circi
Co-founder at SAVA Technologies
Investor perspective
"This could be the defining product in personal health monitoring in the coming decade, and an essential tool for patients and clinicians in diagnosing and treating many chronic diseases as well."
James Wise
Partner, Balderton Capital
Use of funds
- 01Grow the team
- 02Continue product development
- 03Fund research and development
- 04Build out infrastructure
Investors
Categories
About the company
SAVA Technologies
SAVA Technologies develops wearable biosensors for continuous health monitoring.